Immunoassay Market Size & Growth Forecast 2027–2036, By Segments (Product, Specimen, End-use, Technology, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Immunoassay Market size was around USD 29.32 billion in 2026 and is slated to grow at a 4.4% CAGR from 2027 to 2036, surpassing USD 45.1 billion by 2036. The industry revenue for 2027 is calculated at USD 30.41 billion.

• Base Year Value (2026): USD 29.32 billion
• CAGR (2027-2036): 4.40%
• Forecast Year Value (2036): USD 45.1 billion
• Historical Data Period: 2022-2026
• Largest Region: North America
• Forecast Period: 2027-2036

Immunoassay Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America held a 50.24% market share in 2026, supported by advanced diagnostic infrastructure, automated laboratory workflows, established reimbursement systems, and consistently high testing volumes.
  • Asia Pacific is projected to grow at a 4.33% CAGR as laboratory capacity expands, diagnostic access improves, and healthcare providers increase adoption of immunoassay testing for disease detection and monitoring.

• Segment Momentum:

  • Reagents & Kits held a 64.12% share in 2026 because every immunoassay test requires consumables, creating recurring procurement demand across laboratories, hospitals, and diagnostic facilities.
  • Urine is the fastest-growing specimen segment, driven by its non-invasive collection process, ease of handling, and suitability for screening programs seeking greater convenience and accessibility.

• Market Expansion Drivers:

  • Increasing adoption of precision medicine driving biomarker-based immunoassay testing demand.
  • Rising prevalence of cancer and autoimmune disorders accelerating advanced diagnostic assay utilization.
  • Expanding point-of-care immunodiagnostics increasing decentralized testing capabilities across healthcare systems.

• Leading Market Participants:

  Top players in the immunoassay market include Abbott Laboratories (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (United States), Thermo Fisher Scientific Inc. (United States), bioMérieux SA (France), Becton, Dickinson and Company (United States), Sysmex Corporation (Japan), Bio-Rad Laboratories, Inc. (United States), QuidelOrtho Corporation (United States).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2026 Market Size: USD 29.32 billion
  • 2027 Estimated Market Size: USD 30.41 billion.
  • Projected Market Size: USD 45.1 billion by 2036
  • Growth Forecasts: 4.4% CAGR (2027-2036)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Reagents & Kits (Product) | Blood (Specimen) | Hospitals (End-use) | Enzyme Immunoassays (EIA) (Technology) | Infectious Disease Testing (Application)
  • Emerging Opportunity Segment: Software & Services (Product) | Urine (Specimen) | Clinical Laboratories (End-use) | Rapid Test (Technology) | Oncology (Application)

Market Growth Drivers and Industry Trends

Increasing adoption of precision medicine driving biomarker-based immunoassay testing demand

Increasing use of individualized treatment strategies will drive the immunoassay market growth as healthcare providers require reliable biomarker information to characterize diseases and support treatment decisions. Immunoassays can detect and quantify specific proteins, hormones, antibodies, antigens, and other biological markers, making them valuable for patient stratification and disease monitoring. As precision medicine increasingly emphasizes treatment selection based on individual biological characteristics, demand is expanding for testing platforms that can provide consistent biomarker measurements across clinical and laboratory settings.

Rising prevalence of cancer and autoimmune disorders accelerating advanced diagnostic assay utilization

The immunoassay market is expanding alongside the growing diagnostic burden associated with cancer and autoimmune disorders, where detection and monitoring of relevant biological markers can support clinical decision-making. Immunoassay-based techniques are used to identify disease-associated substances and immune responses, helping healthcare professionals assess disease status and monitor patient conditions over time. Increasing demand for earlier diagnosis, treatment monitoring, and differentiated diagnostic workflows is encouraging laboratories and healthcare facilities to adopt more advanced assay technologies for complex disease management.

Expanding point-of-care immunodiagnostics increasing decentralized testing capabilities across healthcare systems

Expansion of decentralized healthcare delivery is strengthening the immunoassay market as point-of-care platforms allow diagnostic testing to be performed closer to patients rather than relying exclusively on centralized laboratories. Portable and rapid immunodiagnostic systems can support timely clinical decisions in hospitals, outpatient facilities, community settings, and other care environments where rapid results are valuable. Improvements in assay sensitivity, portability, workflow simplicity, and instrument integration are enabling broader deployment of immunoassay-based testing across healthcare settings with varying infrastructure capabilities.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Increasing adoption of precision medicine driving biomarker-based immunoassay testing demand	2.00%	High	North America, Europe, Asia Pacific	High	Mid Term
Rising prevalence of cancer and autoimmune disorders accelerating advanced diagnostic assay utilization	1.80%	High	North America, Europe	High	Near Term
Expanding point-of-care immunodiagnostics increasing decentralized testing capabilities across healthcare systems	1.40%	Moderate	Asia Pacific, Latin America	Emerging	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held a 50.24% share of the immunoassay market in 2026, underpinned by advanced diagnostic infrastructure, widespread laboratory testing, and strong adoption of immunoassay technologies across clinical diagnostics, pharmaceutical research, and life sciences applications. The region benefits from sophisticated healthcare systems and continued demand for accurate detection of infectious diseases, hormones, biomarkers, and other clinical indicators. Ongoing advances in diagnostic automation and increasing emphasis on early disease detection further support regional demand.

Asia Pacific represents the fastest-growing region as healthcare infrastructure expands and diagnostic testing becomes more accessible. Rising prevalence of chronic and infectious diseases is increasing the need for reliable laboratory diagnostics, while investments in hospitals and clinical laboratories are improving testing capacity. Growing adoption of automated diagnostic platforms, greater healthcare awareness, and increasing research activity are also accelerating the use of immunoassay technologies across the region.

Key Country Insights

United States

High-Throughput Diagnostics

The U.S. immunoassay market emphasizes automation, laboratory efficiency, and expanding diagnostic applications. Healthcare organizations continue adopting advanced immunoassay platforms that improve testing capacity while supporting personalized medicine and routine clinical diagnostics.

Japan

Precision Diagnostic Innovation

Japan advances the immunoassay market through sophisticated diagnostic technologies designed for accuracy and operational consistency. Manufacturers prioritize compact, high-performance analyzers that integrate efficiently into healthcare facilities and advanced laboratory environments.

South Korea

Smart Laboratory Adoption

South Korea is expanding immunoassay deployment through digitally connected laboratory infrastructure and advanced diagnostic platforms. Healthcare providers increasingly adopt automated testing solutions that improve workflow efficiency and support timely clinical decision-making.

Germany

Laboratory Quality Excellence

Germany focuses on highly reliable immunoassay systems that meet demanding laboratory quality and regulatory standards. Diagnostic providers invest in precision testing technologies and workflow optimization to support hospitals, research institutions, and specialized clinical laboratories.

France

Specialized Clinical Testing

France emphasizes immunoassay technologies for disease monitoring, preventive healthcare, and specialized diagnostic services. Laboratories continue upgrading testing capabilities with automated platforms that enhance analytical consistency and broaden clinical testing applications.

Italy

Diagnostic Workflow Optimization

Italy strengthens its immunoassay market by modernizing laboratory operations and expanding access to automated diagnostic systems. Healthcare institutions prioritize dependable testing platforms that improve operational efficiency while supporting diverse clinical and hospital diagnostic requirements.

Segment Leadership and Growth Trends

 

Product Segment Analysis: Reagents & Kits (Largest Segment) vs Software & Services (Fastest-Growing Segment)

Reagents and kits dominated the immunoassay market with a 64.12% share in 2026, owing to their essential and recurring role in conducting diagnostic and analytical tests. Immunoassay procedures depend on specialized reagents, antibodies, calibrators, and test components to detect and measure target substances accurately. The high volume of routine diagnostic testing across hospitals, laboratories, and research settings supports sustained demand, while the expanding use of immunoassays for disease detection and health monitoring further reinforces the segment's dominant position in 2026.

The software and services segment is the fastest-growing product segment, driven by increasing laboratory automation, digital integration, and demand for efficient data management. Advanced software supports test result analysis, workflow optimization, instrument connectivity, and quality control, while service offerings help maintain reliable operation of increasingly sophisticated diagnostic systems. The growing focus on laboratory efficiency and connected healthcare infrastructure is accelerating demand for integrated software and service solutions.

Specimen Segment Analysis: Blood (Largest Segment) vs Urine (Fastest-Growing Segment)

The blood specimen segment held the largest share of the immunoassay market at 44.03% in 2026, supported by its extensive use across clinical diagnostics and disease monitoring. Blood samples provide access to a broad range of biomarkers, antibodies, hormones, proteins, and other analytes, making them highly suitable for numerous immunoassay applications. The established role of blood testing in hospitals, diagnostic laboratories, and routine health assessments continues to underpin the segment's leading position.

The urine specimen segment is the fastest-growing segment, benefiting from the convenience and non-invasive nature of urine collection. Urine-based immunoassays are widely applicable in screening and diagnostic settings where rapid, accessible, and patient-friendly testing is important. Increasing demand for simplified testing procedures, broader adoption of point-of-care diagnostics, and the suitability of urine samples for various screening applications are supporting the segment's expansion.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Product	Reagents & Kits, Analyzers/Instruments, Software & Services	Reagents & Kits	Software & Services
Specimen	Blood, Saliva, Urine, Others	Blood	Urine
End-use	Hospitals, Blood Banks, Clinical Laboratories, Pharmaceutical and Biotech Companies, Academic Research Centers, Others	Hospitals	Clinical Laboratories
Technology	Radioimmunoassay (RIA), Enzyme Immunoassays (EIA), Chemiluminescence Immunoassays (CLIA), Fluorescence Immunoassays (FIA), Rapid Test, Others	Enzyme Immunoassays (EIA)	Rapid Test
Application	Therapeutic Drug Monitoring, Oncology, Cardiology, Endocrinology, Infectious Disease Testing, Autoimmune Diseases, Others	Infectious Disease Testing	Oncology

Competitive Landscape and Market Positioning

Major players in the immunoassay market:

1. Abbott Laboratories (United States)

2. F. Hoffmann-La Roche Ltd. (Switzerland)

3. Siemens Healthineers AG (Germany)

4. Danaher Corporation (United States)

5. Thermo Fisher Scientific Inc. (United States)

6. bioMérieux SA (France)

7. Becton Dickinson and Company (United States)

8. Sysmex Corporation (Japan)

9. Bio-Rad Laboratories Inc. (United States)

10. QuidelOrtho Corporation (United States)

The immunoassay market is experiencing rapid innovation driven by demand for highly sensitive and automated diagnostic solutions. Companies are introducing advanced assay platforms that support faster detection, multiplex testing, and improved clinical accuracy across healthcare applications. Increased integration of automation and digital analysis tools is further strengthening efficiency and competitiveness within the immunoassay market.

Industry Development/News

Company Name	Date	Key Development
ARCHIMED Diagnostics	Oct-25	ARCHIMED Diagnostics acquired ARK Diagnostics in a transaction valued at $428 million. This acquisition expands the firm's specialty immunoassay in vitro diagnostics portfolio and strengthens its underlying diagnostics platform capabilities.
bioMérieux	Jan-25	bioMérieux acquired SpinChip Diagnostics ASA, securing a point-of-care immunoassay platform capable of delivering diagnostic results within ten minutes. This integration significantly bolsters the company’s rapid diagnostics portfolio and point-of-care market position.
QuidelOrtho Corporation	Feb-26	QuidelOrtho entered a strategic supply agreement with Lifotronic Technology to expand its global immunoassay portfolio with new analyzer platforms and over 25 assays. The partnership enhances its high-throughput diagnostic offerings and scales commercial reach across Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
Spear Bio	Aug-25	Spear Bio established a strategic distribution partnership with Bio-Techne to accelerate the commercialization of its next-generation, ultrasensitive immunoassay technology. The collaboration targets both life science research and clinical diagnostics sectors to drive the adoption of its proprietary platform.
MeMed	Apr-26	MeMed received CE Mark approval for its rapid host-response test, which differentiates between bacterial and viral infections in approximately 20 minutes. This regulatory milestone supports the integration of sophisticated immunoassay-based diagnostic solutions into routine clinical workflows.
Fujirebio	Jan-26	Fujirebio launched the Lumipulse G pTau 217 CSF assay for its automated LUMIPULSE G analyzers. This development expands chemiluminescent enzyme immunoassay-based neurological testing capabilities, addressing the growing demand for automated, high-throughput biomarker measurement in Alzheimer’s disease research and diagnostics.
Siemens Healthineers	Dec-25	Siemens Healthineers partnered with ALZpath to integrate the pTau217 antibody into a new in vitro diagnostic assay for Alzheimer’s disease. This strategic collaboration strengthens the company’s neurodegenerative disease immunoassay portfolio and advances its capability to provide standardized biomarker testing.
Quanterix Corporation	Jun-25	Quanterix secured Class 1 Medical Device registration in South Korea for its HD-X Simoa Immunoassay Analyzer. This regulatory approval facilitates the expansion of its ultra-sensitive immunoassay platform within the Asia-Pacific region, increasing market access for advanced protein analysis.
T&D Diagnostics	Apr-25	T&D Diagnostics commenced domestic manufacturing of its Starkwert FIA product range in India. This investment in local production capabilities enhances the company's ability to supply fluorescence immunoassay diagnostic solutions to the regional market.
Anbio Biotechnology	Jan-25	Anbio Biotechnology launched the ADL-1000, a Dry Chemiluminescence Immunoassay solution featuring freeze-dried reagents and whole-blood testing. The system is designed to streamline laboratory workflows and reduce costs, expanding the application of chemiluminescence diagnostics across infectious, cardiovascular, and neurological disease testing.